A Randomized, Multicenter, Open-Label Phase 3 Study to Evaluate the Safety and Efficacy of Infliximab in Pediatric Patients With Moderate to Severe Ulcerative Colitis
Jeffrey S. Hyams(Connecticut Children's Medical Center), Anne M. Griffiths(University of Toronto), Lakshmi Damaraju(Janssen (Belgium)), James Markowitz, Gigi Veereman, Marion Blank(Janssen (United States)), Cynthia Guzzo(Janssen (Belgium)), Stanley A. Cohen(Troy Gastroenterology), Harland S. Winter(Massachusetts General Hospital), Wallace Crandall, Subra Kugathasan(Children's Healthcare of Atlanta), Jewel Johanns(Janssen (United States)), Robert N. Baldassano(Children's Hospital of Philadelphia)
Cited by 2
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k